Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310. 2Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева.
Список исп. литературыСкрыть список 1. Беккер РА, Быков ЮВ. Мемантин: возможности и перспективы применения в психиатрии (Обзор современных данных) //Психиатрия и психофармакотерапия. 2016;4(18):42-51. 2. Беккер РА, Быков ЮВ. Мемантин: обзор применения в неврологии //Психиатрия и психофармакотерапия. 2017;1(9):34-43. 3. Васенина ЕЕ, Ганькина ОА, Левин ОС. Добавление мемантина к галантамину повышает эффективность лечения у пациентов с умеренной степенью тяжести деменции с тельцами Леви //Журнал неврологии и психиатрии им. C.C. Корсакова. 2018. Т. 118. № 6-2. С. 32-36. 4. Колыхалов И.В. Поведенческие и антипсихотические эффекты мемантина у пациентов с деменцией //Психиатрия. 2008. № 4-6 (34-36). С. 65-69. 5. Левин ОС, Батукаева ЛА, Смоленцева ИГ, Амосова НА. Эффективность и безопасность мемантина при деменции с тельцами Леви //Журнал неврологии и психиатрии им. C.C. Корсакова. 2008. Т. 108. № 5. С. 39-46. 6. Левин ОС, Батукаева ЛА. Эффективность мемантина при болезни Паркинсона с деменцией //Журнал неврологии и психиатрии им. C.C. Корсакова. 2008. Т. 108. № 12. С. 16-24. 7. Лузин МН, Кривонос ОВ, Кожевникова ЖВ. Акатинол мемантин в терапии когнитивных расстройств при болезни Паркинсона //Журнал неврологии и психиатрии им. C.C. Корсакова. 2007. Т. 107. № 1. С. 26-30. 8. Любов ЕБ, Митина ЮВ, Сюмкина ОВ и др. Клинико-функциональный и ресурсосберегающий эффекты лечения мемантином деменции Альцгеймеровского типа и сосудистой деменции //Социальная и клиническая психиатрия. 2010. Т. 20. № 1. С. 43-51. 9. Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multi-centre trial. Lancet Neurol. 2009;8:613–618. 10. Atri A. Current and future treatments in Alzheimer’s disease. Semin Neurol. 2019;39:227-240. 11. Bachyns'ka NIu, Rozheliuk IF, Polietaieva KM, Kholin VO. [Use of memantine for elderly patients in the mild stage of Alzheimer's and vascular dementia]. [Article in Ukrainian]. Lik Sprava. 2013;(7):80-96. 12. Barnham KJ, Bush AI. Biological metals and metal-targeting compounds in major neurodegenerative diseases. Chem. Soc. Rev. 2014;43:6727–6749. 13. Boxer AL, Lipton AM, Womack K et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23:211–217. 14. Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry. 1999;14(1):3-47. 15. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. Neurochem. 2006;97:1611–1626. 16. Chow TW, Fam D, Graff-Guerrero A et al. Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: An open-label pilot study. Int J Geriatr Psychiatry. 2013;28:319–325. 17. Chow TW, Graff-Guerrero A, Verhoeff NP et al. Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatr Dis Treat. 2011;7:415–424. 18. Cumbo E, Ligori LD. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer’s disease: A 12-month, randomized, open-label trial. J Alzheimers Dis 2014;39:477–485. 19. Cunningham EL, McGuinness B, Herron B, Passmore AP. Dementia. Ulster Med. J. 2015;84:79–87. 20. Custodio N, Montesinos R, Lira D et al. Mixed dementia: A review of the evidence. Dement Neuropsychol. 2017;11(4):364-370. 21. Doody RS, Tariot PN, Pfeiffer E et al. Meta-analysis of six-month memantine trials in Alzheimer’s disease. Alzheimers Dement. 2007;3:7–17. 22. EMEA Committee for Medicinal products for Human Use. Plenary meeting monthly report. 17‐11‐2005. October 2005 Vol. http://www.emea. europa.eu/pdfs/human/press/pr/36234805en.pdf. 23. Emre M, Tsolaki M, Bonucelli U et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–977. 24. European Commission. Memantine receives European‐wide approval for once‐daily dosing. http://www.alzheimer‐europe.org/?content=shnw& shnwid=5976E167EBBA. 25. European Medicines Agency. Ebixa. European Public Assessment Report. www.emea.eu.int/humandocs/Humans/EPAR/ebixa/ebixa.htm 2004. 26. FDA approves Namenda(TM) (Memantine HCl) for the treatment of moderate to severe Alzheimer's disease. http://ir.frx.com/phoenix.zhtml?c= 83198&p=irol‐newsArticle&ID=459801&highlight=.. 27. Folch J, Busquets O, Ettcheto M. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J Alzheimers Dis. 2018;62(3):1223–1240. 28. Grossberg GT, Pejović V, Miller ML et al. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord.2009;27:164–172. 29. Howard R, McShane R, Lindesay J, et al. Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer’s disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2015;14:1171-1181. 30. Johansson C, Ballard C, Hansson O et al. Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. Int. J. Geriatr. Psychiatry. 2011;26:206–213. 31. Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer’s disease in Sweden. Am J Geriatr Pharmacother. 2005;3:77–86. 32. Kane JPM, Surendranathan A, Bentley A et al. Clinical prevalence of Lewy body dementia. Alzheimers Res Ther. 2018;10(1):19. 33. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6:782–792. 34. Kishita N, Backhouse T, Mioshi E. Nonpharmacological interventions to improve depression, anxiety, and quality of life (QoL) in people with dementia: an overview of systematic reviews. J Geriatr Psychiatry Neurol. 2019;33:28-41. 35. Kodis EJ, Choi S, Swanson E et al. N-methyl-D-aspartate receptor-mediated calcium influx connects amyloid-β oligomers to ectopic neuronal cell cycle reentry in Alzheimer’s disease. Alzheimer’s Dement. 2018;14:1302–1312. 36. Koola MM, Parsaik AK. Galantamine-memantine combination effective in dementia: Translate to dementia praecox? Schizophr Res Cogn. 2018;12:8-10. 37. Kuns B, Rosani A, Varghese D. Memantine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. 38. Larsson V, Engedal K, Aarsland D et al. Quality of life and the effect of memantine in dementia with Lewy bodies and Parkinson’s disease dementia. Dement. Geriatr. Cogn. Disord. 2011;32:227–234. 39. Lavretsky H, Laird KT, Krause-Sorio B et al. A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints. Am J Geriatr Psychiatry. 2020;28(2):178-190. 40. Leroi I, Overshott R, Byrne EJ et al. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov. Disord. 2009;24:1217–1221. 41. Levin O, Yunishchenko N, Dudarova M. Efficacy of akatinol memantine in moderate cognitive impairments. Neurosci Behav Physiol. 2010;40:926–933. 42. Links KA, Black SE, Graff-Guerrero A et al. A case of apathy due to frontotemporal dementia responsive to memantine. Neurocase. 2013;19:256–261. 43. Lipton S. NMDA receptor activity regulates transcription of antioxidant pathways. Nat. Neurosci. 2008;11:381–382. 44. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat. Rev. Drug Discov. 2006;5:160–170. 45. Lipton SA. Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 2007;8:803–808. 46. Litvinenko IV, Odinak MM, Mogil’naya VI, Perstnev SV. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson’s disease complicated by dementia. Neurosci Behav Physiol. 2010;40(2):149–55. 47. Maskell PD, Speder P, Newberry NR, Bermudez I. Inhibition of human α7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. Br J Pharmacol. 2003;140:1313–1319. 48. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: A systematic review and meta-analysis. 2015;PLoS One 10:e0123289. 49. Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis. Exp Ther Med. 2019;17(3):1611-1624. 50. Mitrečić D, Petrović DJ, Stančin P et al. How to face the aging world - lessons from dementia research. Croat Med J. 2020;61(2):139-146. 51. Mobius HJ, Stoffler A. Memantine in vascular dementia. Int Psychogeriatr. 2003;15(1):207–213. 52. Nakamura T, Lipton SA. Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: Possible pharmacological strategies. Cell Calcium. 2010;47:190–197. 53. Orgogozo JM, Rigaud AS, Stoffler A et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300) Stroke. 2002;33(7):1834–1839. 54. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: Complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox. Res. 2013;24:358–369. 55. Patterson C. Alzheimer's Disease International; London: 2018. World Alzheimer report 2018. 56. Peters O, Lorenz D, Fesche A et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging. 2012;16:544–548. 57. Procter AW, Qurne M, Francis PT. Neurochemical features of fronto-temporal dementia. Dement Geriatr Cogn Disord. 1999;10(Suppl. 1):80–84. 58. Reisberg B, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–1341. 59. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003;9(3):275-308. 60. Santos MA, Chand K, Chaves S. Recent progress in multifunctional metal chelators as potential drugs for Alzheimer’s disease. Coord. Chem. Rev. 2016;327–328:287–303. 61. Schachter AS, Davis KL. Alzheimer's disease. Dialogues Clin Neurosci. 2000;2(2):91-100. 62. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge university press, 2013. 626 p. ISBN 978-1107686465. 63. Suzuki H, Inoue Y, Nishiyama A et al. Clinical efficacy and changes in the dosages of concomitantly used psychotropic drugs in memantine therapy in Alzheimer’s disease with behavioral and psychological symptoms on dementia. Ther Adv Psychopharmacol.2013;3:123–128. 64. Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: A case series. Alzheimer Dis Assoc Disord. 2007;21:164–166. 65. Takahashi H, Xia P, Cui J et al. Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. Sci. Rep. 2015;5:14781. doi: 10.1038/srep14781. 66. Talantova M., Sanz-Blasco S., Zhang, Xia P et al. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2013;110:E2518–E2527. 67. Tan CC, Yu JT, Wang HF et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. J Alzheimers Dis. 2014;41:615–631. 68. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA.2004;291:317–324. 69. Thakur TK, Albanese E, Giannakopoulos P et al. In: Neurological disorders. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities. 3rd ed. Patel V, Chisholm D, Dua T, Laxminarayan R, Medina M, editors. The International Bank for Reconstruction and Development/The World Bank; Washington, DC, USA: 2016. 70. Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging. 2009;4:367. 71. Tomimoto H. [Subcortical vascular dementia: significance in the differential diagnosis of dementia]. [Article in Japanese]. Rinsho Shinkeigaku. 2011;51(11):940-2. 72. Tricco AC, Ashoor HM, Soobiah C et al. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer’s disease: systematic review and network metaanalysis. J Am Geriatr Soc. 2018;66: 170-178. 73. Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease. Mol. Neurodegener. 2014;9:48. 74. Uwagbai O, Kalish VB. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 24, 2020. Vascular Dementia. 75. Vaci N, Koychev I, Kim CH. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study. Br J Psychiatry. 2020;1-7. 76. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) Int Clin Psychopharmacol. 2002;17(6):297–305. 77. Wilcock GK, Ballard CG, Cooper JA et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: A pooled analysis of 3 studies. J Clin Psychiatry. 2008;69:341–348. 78. Wong KH, Riaz MK, Xie Y et al. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier. Int J Mol Sci. 2019;20(2). 79. Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J. Neurosci. 2010;30:11246–11250. 80. Young JJ, Lavakumar M, Tampi D et al. Frontotemporal dementia: latest evidence and clinical implications. Ther Adv Psychopharmacol. 2018;8(1):33-48. 81. Yue A, Han X, Mao E et al. The effect of scalp electroacupuncture combined with Memantine in patients with vascular dementia: A retrospective study. Medicine (Baltimore). 2020;99(33):e21242. 82. Zhang N, Wei C, Du H et al. The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-to-moderate Alzheimer’s disease patients. Dement Geriatr Cogn Disord. 2015;40:85–93. 83. EudraCT No.: 2013-003408-38 - Bioequivalence study on memantine preparations TINGREKS 10 mg film-coated tablets (JSC Grindeks, Latvia) versus Ebixa 10 mg film-coated tablets (H. Lundbeck A/S, Denmark) in healthy volunteers under fasting conditions, 2013.